BGB-24714 + paclitaxel + carboplatin

**BGB-24714 + paclitaxel + carboplatin** is an investigational combination therapy for advanced or metastatic solid tumors, currently being studied in phase 1 clinical trials. \n- **BGB-24714** is a small molecule oral inhibitor that mimics Second Mitochondria-derived Activator of Caspases (SMAC), antagonizing inhibitor of apoptosis proteins (IAPs) to induce cancer cell apoptosis[1][3][5][7]. \n- **Paclitaxel** is a microtubule stabilizer that promotes apoptosis by interfering with cell division during mitosis[2][4][6][8]. \n- **Carboplatin** is a platinum-based chemotherapy agent that causes DNA cross-linking and induces apoptosis by interfering with DNA repair[2][4][6][8].\n\nThis combination is being studied to evaluate synergistic efficacy and safety profiles for solid tumors in patients previously treated or lacking other options. \nDeveloper: BeiGene. \nPrimary Indication: Advanced or metastatic solid tumors[1][3][5][7][9].